Editas Medicine, Inc. Profile Avatar - Palmy Investing

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops …

Biotechnology
US, Cambridge [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group

Peers Performance

A quick analysis that compared Editas Medicine, Inc. (EDIT) to it's peer group.

No peer comparison plottable.

End of EDIT's Analysis
CIK: 1650664 CUSIP: 28106W103 ISIN: US28106W1036 LEI: - UEI: -
Secondary Listings
EDIT has no secondary listings inside our databases.